Madhavan Mahesh V, Kirtane Ajay J
Herbert and Sandi Feinberg Interventional Cardiology and Heart Valve Center at Columbia University Medical Center/New York-Presbyterian Hospital, 161 Fort Washington Avenue, 6th Floor, New York, NY, 10032, USA.
Curr Cardiol Rep. 2015 Jun;17(6):41. doi: 10.1007/s11886-015-0598-4.
The number of patients who undergo percutaneous coronary intervention (PCI) and additionally require chronic anticoagulation for a variety of indications is not insignificant. The choice of antithrombotic therapy after PCI in patients with chronic indications for anticoagulation therapy remains a challenge for interventional cardiologists, as the risk of bleeding must be adequately weighed against the benefit of preventing future ischemic events. While these clinical scenarios are encountered in approximately 10 % of patients undergoing PCI, current practice guidelines do not sufficiently guide physicians as to how to best treat these PCI patients requiring chronic anticoagulation. Notwithstanding the clinical difficulties of treating such patients, there are several recent studies and analyses that have assessed optimal antithrombotic strategies in the PCI population, and there are several others that are currently underway. This review evaluates the currently available data and clinical scenarios commonly encountered by treating physicians.
接受经皮冠状动脉介入治疗(PCI)且因各种适应症还需要长期抗凝治疗的患者数量相当可观。对于有抗凝治疗慢性适应症的患者,PCI术后抗栓治疗的选择仍然是介入心脏病学家面临的一项挑战,因为必须在出血风险与预防未来缺血事件的获益之间进行充分权衡。虽然在约10%接受PCI的患者中会遇到这些临床情况,但目前的实践指南并未充分指导医生如何最佳治疗这些需要长期抗凝的PCI患者。尽管治疗此类患者存在临床困难,但最近有几项研究和分析评估了PCI人群中的最佳抗栓策略,还有其他几项研究正在进行中。本综述评估了目前可用的数据以及治疗医生常见的临床情况。